{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Happe M"],"funding":["NCI NIH HHS","Division of Intramural Research, National Institute of Allergy and Infectious Diseases"],"pagination":["67"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10980745"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(1)"],"pubmed_abstract":["Ebola virus disease (EVD) is a filoviral infection caused by virus species of the Ebolavirus genus including Zaire ebolavirus (EBOV) and Sudan ebolavirus (SUDV). We investigated the safety and immunogenicity of a heterologous prime-boost regimen involving a chimpanzee adenovirus 3 vectored Ebola vaccine [either monovalent (cAd3-EBOZ) or bivalent (cAd3-EBO)] prime followed by a recombinant modified vaccinia virus Ankara EBOV vaccine (MVA-EbolaZ) boost in two phase 1/1b randomized open-label clinical trials in healthy adults in the United States (US) and Uganda (UG). Trial US (NCT02408913) enrolled 140 participants, including 26 EVD vaccine-naïve and 114 cAd3-Ebola-experienced participants (April-November 2015). Trial UG (NCT02354404) enrolled 90 participants, including 60 EVD vaccine-naïve "],"journal":["NPJ vaccines"],"pubmed_title":["Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials."],"pmcid":["PMC10980745"],"funding_grant_id":["75N91019D00024"],"pubmed_authors":["Nesheim W","Dropulic LK","Kelley CF","Carr D","Courneya J","Hu Z","Grimes V","Zephir KL","Strom L","Ploquin A","Costner PJM","Nakibuuka L","DeCederfelt H","Kimbugne G","Gordon IJ","Ananworanich J","Larkin B","Sullivan NJ","Chen GL","Chrisley L","Xu J","Beck A","Girmay T","Sanders J","Ledgerwood JE","Chen WH","Mulligan MJ","Nakabuye I","Novik L","Campbell JD","Lee M","Stanley DA","Stein J","Gaudinski MR","Koup RA","Berkowitz NM","Billington M","Whalen WR","Ashman C","Hofstetter AR","Bailer RT","Luzinda K","Cham F","Casazza JP","Greenberg N","Kamya MR","Kwon A","Mascola JR","Kajumba F","Happe M","Michael NL","Sitar S","Osinski E","Sadowski J","Kiweewa F","Murray T","Plummer SH","Straling J","Wang J","Coates EE","Kaltovich F","DeZure A","Rouphael N","Tsukerman S","Kibuuka H","Wang X","Mendoza F","Pittman IR","Wakabi S","Ogilvie M","Dorsey B","Lyke KE","Mwesigwa B","Enama ME","Hendel CS","Bailey CA","Houser KV","Becker J","VRC 208 and RV 422 study team","Bower M","Komninou P","Edupuganti S","Nguyen TA","Tindikahwa A","Vasilenko O","Matovu R","Kabbani S","Schwartz R","Ake JA","Mukyala MG","Holman LA","Millard M","Graham BS","Conan-Cibotti M","Kabahubya M","Robb ML","Yamshchikov GV","Lai L"],"additional_accession":[]},"is_claimable":false,"name":"Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials.","description":"Ebola virus disease (EVD) is a filoviral infection caused by virus species of the Ebolavirus genus including Zaire ebolavirus (EBOV) and Sudan ebolavirus (SUDV). We investigated the safety and immunogenicity of a heterologous prime-boost regimen involving a chimpanzee adenovirus 3 vectored Ebola vaccine [either monovalent (cAd3-EBOZ) or bivalent (cAd3-EBO)] prime followed by a recombinant modified vaccinia virus Ankara EBOV vaccine (MVA-EbolaZ) boost in two phase 1/1b randomized open-label clinical trials in healthy adults in the United States (US) and Uganda (UG). Trial US (NCT02408913) enrolled 140 participants, including 26 EVD vaccine-naïve and 114 cAd3-Ebola-experienced participants (April-November 2015). Trial UG (NCT02354404) enrolled 90 participants, including 60 EVD vaccine-naïve ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Mar","modification":"2026-06-01T21:47:49.977Z","creation":"2025-04-22T08:17:26.526Z"},"accession":"S-EPMC10980745","cross_references":{"pubmed":["38553525"],"doi":["10.1038/s41541-024-00833-z"]}}